BRPI1014527A2 - composição de lipossoma - Google Patents

composição de lipossoma

Info

Publication number
BRPI1014527A2
BRPI1014527A2 BRPI1014527A BRPI1014527A BRPI1014527A2 BR PI1014527 A2 BRPI1014527 A2 BR PI1014527A2 BR PI1014527 A BRPI1014527 A BR PI1014527A BR PI1014527 A BRPI1014527 A BR PI1014527A BR PI1014527 A2 BRPI1014527 A2 BR PI1014527A2
Authority
BR
Brazil
Prior art keywords
liposome composition
liposome
composition
Prior art date
Application number
BRPI1014527A
Other languages
English (en)
Inventor
Hiroshi Ishihara
Hiroshi Kikuchi
Kenji Hyodo
Original Assignee
Esai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42828273&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1014527(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Esai R&D Man Co Ltd filed Critical Esai R&D Man Co Ltd
Publication of BRPI1014527A2 publication Critical patent/BRPI1014527A2/pt
Publication of BRPI1014527B1 publication Critical patent/BRPI1014527B1/pt
Publication of BRPI1014527B8 publication Critical patent/BRPI1014527B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
BRPI1014527A 2009-03-30 2010-03-30 composição farmacêutica na forma de lipossoma e método de fabricação da mesma BRPI1014527B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16465309P 2009-03-30 2009-03-30
US61/164.653 2009-03-30
JP2009082521 2009-03-30
JP2009-082521 2009-03-30
PCT/JP2010/055770 WO2010113984A1 (ja) 2009-03-30 2010-03-30 リポソーム組成物

Publications (3)

Publication Number Publication Date
BRPI1014527A2 true BRPI1014527A2 (pt) 2016-04-05
BRPI1014527B1 BRPI1014527B1 (pt) 2020-11-24
BRPI1014527B8 BRPI1014527B8 (pt) 2021-05-25

Family

ID=42828273

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1014527A BRPI1014527B8 (pt) 2009-03-30 2010-03-30 composição farmacêutica na forma de lipossoma e método de fabricação da mesma

Country Status (33)

Country Link
US (3) US20120058178A1 (pt)
EP (1) EP2415470B1 (pt)
JP (1) JP5551683B2 (pt)
KR (1) KR101495951B1 (pt)
CN (1) CN102369008B (pt)
AU (1) AU2010232347A1 (pt)
BR (1) BRPI1014527B8 (pt)
CA (1) CA2756811C (pt)
CO (1) CO6430500A2 (pt)
CY (1) CY1118231T1 (pt)
DK (1) DK2415470T3 (pt)
ES (1) ES2593027T3 (pt)
HK (1) HK1165707A1 (pt)
HR (1) HRP20161157T1 (pt)
HU (1) HUE029577T2 (pt)
IL (1) IL215059A (pt)
LT (1) LT2415470T (pt)
MA (1) MA33127B1 (pt)
ME (1) ME02518B (pt)
MX (1) MX2011009632A (pt)
MY (1) MY160203A (pt)
NZ (1) NZ595212A (pt)
PE (2) PE20120923A1 (pt)
PL (1) PL2415470T3 (pt)
PT (1) PT2415470T (pt)
RS (1) RS55148B1 (pt)
SG (1) SG174255A1 (pt)
SI (1) SI2415470T1 (pt)
SM (1) SMT201600307B (pt)
TW (1) TWI392519B (pt)
UA (1) UA103794C2 (pt)
WO (1) WO2010113984A1 (pt)
ZA (1) ZA201106535B (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11071713B2 (en) 2009-03-30 2021-07-27 Eisai R&D Management Co., Ltd. Liposome composition

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
CN101209243B (zh) * 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
WO2010113983A1 (ja) 2009-03-30 2010-10-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 リポソーム組成物の製造方法
RU2561582C2 (ru) * 2010-11-19 2015-08-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Инъекционная лекарственная форма олигопептидного препарата для лечения рассеянного склероза и способ ее получения
WO2012119077A1 (en) 2011-03-02 2012-09-07 Morphotek Inc. Co -administration of eribulin and farletuzumab for the treatment of breast cancer
SG10201706239VA (en) * 2013-02-01 2017-08-30 Zoneone Pharma Inc Remote loading of sparingly water-soluble drugs into liposomes
AU2015301234A1 (en) 2014-08-04 2017-06-15 Zoneone Pharma, Inc. Remote loading of sparingly water-soluble drugs into lipid vesicles
EP3265063A4 (en) 2015-03-03 2018-11-07 Cureport, Inc. Dual loaded liposomal pharmaceutical formulations
HRP20211776T8 (hr) 2015-09-18 2022-03-18 Technische Universität München Ligandi za integrin alfavbeta6, njihova sinteza i upotreba
JP6564873B2 (ja) * 2015-11-02 2019-08-21 富士フイルム株式会社 リポソーム組成物およびその製造方法
WO2017188350A1 (ja) 2016-04-28 2017-11-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍の成長を抑制する方法
KR20190122676A (ko) * 2017-01-18 2019-10-30 테마섹 라이프 사이언스 래보러토리 리미티드 유사분열기세포의 표적화를 증가시키는 고안정화된 리포좀
US11332498B2 (en) 2017-03-17 2022-05-17 Technische Universitat Munchen Ligands for integrin αVβ8, synthesis and uses thereof
CA3058127C (en) * 2017-03-31 2022-07-05 Fujifilm Corporation Liposome composition and pharmaceutical composition
WO2019097073A1 (en) 2017-11-20 2019-05-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US20230201119A1 (en) * 2020-05-29 2023-06-29 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Liposome containing ethylenediamine tetraacetic acid or salt thereof and eribulin or pharmaceutically acceptable salt thereof
CN115957351B (zh) * 2022-11-15 2023-06-27 中国人民解放军海军第九七一医院 一种碘海醇注射液及其制备方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736155A (en) * 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
GB9126209D0 (en) 1991-12-10 1992-02-12 Orion Yhtymae Oy Drug formulations for parenteral use
CA2161225C (en) 1993-04-22 2003-07-01 Sinil Kim Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
FR2736056B1 (fr) 1995-06-29 1997-08-08 Commissariat Energie Atomique Derives de cyclodextrines, leur preparation et leur utilisation pour incorporer des molecules hydrophobes dans des systemes de tensioactifs organises
US6051251A (en) 1997-11-20 2000-04-18 Alza Corporation Liposome loading method using a boronic acid compound
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
DE122011100031I1 (de) 1998-06-17 2011-12-15 Eisai R&D Man Co Ltd Makrocyclische analoga und verfahren zu ihrer verwendung und herstellung.
US6593308B2 (en) 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
CN1116875C (zh) 2000-10-19 2003-08-06 南京振中生物工程有限公司 紫杉醇脂质组合物及其制备方法
AU2002340669A1 (en) 2001-11-13 2003-05-26 Celator Technologies, Inc. Lipid carrier compositions with enhanced blood stability
ES2290333T3 (es) 2001-11-13 2008-02-16 Celator Pharmaceuticals, Inc. Composiciones de vehiculos lipidicos y metodos para la retencion mejorada de farmacos.
DE10255106A1 (de) 2002-11-24 2004-06-09 Novosom Ag Liposomale Glucocorticoide
WO2004047800A2 (en) 2002-11-26 2004-06-10 Gilead Sciences, Inc. Method of drug loading in liposomes by gradient
JP5355842B2 (ja) * 2002-12-31 2013-11-27 ザイダス ビーエスヴィ ファーマ プライベート リミテッド 非ペギレート化長循環性リポソーム
WO2004089419A1 (ja) * 2003-04-04 2004-10-21 The University Of Tokyo 抗ｍｔ－ｍｍｐモノクローナル抗体含有脂質膜構造体
US6747011B1 (en) 2003-06-04 2004-06-08 A.P. Group, Inc. Antitumor drugs and methods
US20050129753A1 (en) 2003-11-14 2005-06-16 Gabizon Alberto A. Method for drug loading in liposomes
CA2553573A1 (en) 2004-01-29 2005-08-11 Eisai R & D Management Co., Ltd. Method for stabilizing macrolide compound
US8147867B2 (en) * 2004-05-03 2012-04-03 Hermes Biosciences, Inc. Liposomes useful for drug delivery
DE602005018043D1 (de) 2004-05-17 2010-01-14 Tekmira Pharmaceuticals Corp Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
CA3028453C (en) 2004-06-03 2021-07-27 Eisai R&D Management Co., Ltd. Intermediates for the preparation of analogs of halichondrin b
AU2005291807B2 (en) 2004-10-06 2012-04-19 Bc Cancer Agency Liposomes with improved drug retention for treatment of cancer
TWI373473B (en) 2005-09-02 2012-10-01 Otsuka Pharma Co Ltd Anticancer agent
CN101209243B (zh) 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
US20090196913A1 (en) 2007-05-11 2009-08-06 Ken Shi Kun Huang Anti-Alpha-V Immunoliposome Composition, Methods, and Uses
US20090196918A1 (en) 2008-02-01 2009-08-06 University Of Kentucky Research Foundation Liposomal formulations of hydrophobic lactone drugs in the presence of metal ions
WO2010113983A1 (ja) 2009-03-30 2010-10-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 リポソーム組成物の製造方法
ES2593027T3 (es) 2009-03-30 2016-12-05 Eisai R&D Management Co., Ltd. Composición liposomal
WO2011094339A1 (en) 2010-01-26 2011-08-04 Eisai R&D Management Co., Ltd. Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs
EP2693875A4 (en) 2011-04-08 2014-10-22 British Columbia Cancer Agency BISPHENOL COMPOUNDS AND METHODS OF USE
WO2013012891A1 (en) 2011-07-19 2013-01-24 Stc. Unm Intraperitoneally-administered nanocarriers that release their therapeutic load based on the inflammatory environment of cancers
CN105338977B (zh) 2013-06-26 2018-10-16 卫材R&D管理有限公司 艾日布林和乐伐替尼作为治疗癌症的联合疗法的用途
EP3046543A1 (en) 2013-09-18 2016-07-27 Stc.Unm Torroidal mesoporous silica nanoparticles (tmsnps) and related protocells
WO2015095784A1 (en) 2013-12-19 2015-06-25 Luminus Biosciences, Inc. Solid nanoparticle formulation of microtubule inhibitors with reduced ostwald ripening for oral administration
RU2016136504A (ru) 2014-03-03 2018-04-03 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. ПРИМЕНЕНИЕ ЭРИБУЛИНА И ИНГИБИТОРОВ mTOR В КАЧЕСТВЕ КОМБИНИРОВАННОЙ ТЕРАПИИ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ
EP3148336B1 (en) 2014-05-28 2019-10-02 Eisai R&D Management Co., Ltd. Eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
CN105640935A (zh) 2014-11-12 2016-06-08 天津市汉康医药生物技术有限公司 供注射用甲磺酸艾日布林药物组合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11071713B2 (en) 2009-03-30 2021-07-27 Eisai R&D Management Co., Ltd. Liposome composition

Also Published As

Publication number Publication date
US20210023004A1 (en) 2021-01-28
KR20110122219A (ko) 2011-11-09
PE20120923A1 (es) 2012-08-27
DK2415470T3 (en) 2016-09-19
SI2415470T1 (sl) 2016-12-30
HUE029577T2 (en) 2017-03-28
JPWO2010113984A1 (ja) 2012-10-11
US20140044777A1 (en) 2014-02-13
EP2415470A4 (en) 2012-11-28
EP2415470B1 (en) 2016-07-06
NZ595212A (en) 2014-02-28
JP5551683B2 (ja) 2014-07-16
UA103794C2 (en) 2013-11-25
ES2593027T3 (es) 2016-12-05
MA33127B1 (fr) 2012-03-01
ZA201106535B (en) 2012-05-30
TWI392519B (zh) 2013-04-11
CA2756811A1 (en) 2010-10-07
CY1118231T1 (el) 2017-06-28
WO2010113984A1 (ja) 2010-10-07
SG174255A1 (en) 2011-10-28
HRP20161157T1 (hr) 2016-11-18
PT2415470T (pt) 2016-08-31
EP2415470A1 (en) 2012-02-08
MY160203A (en) 2017-02-28
CN102369008A (zh) 2012-03-07
RS55148B1 (sr) 2016-12-30
MX2011009632A (es) 2011-10-19
HK1165707A1 (zh) 2012-10-12
CA2756811C (en) 2014-09-23
CO6430500A2 (es) 2012-04-30
US20120058178A1 (en) 2012-03-08
TW201102110A (en) 2011-01-16
KR101495951B1 (ko) 2015-02-25
IL215059A (en) 2016-03-31
US11071713B2 (en) 2021-07-27
PL2415470T3 (pl) 2016-12-30
SMT201600307B (it) 2016-11-10
PE20151519A1 (es) 2015-10-28
ME02518B (me) 2017-02-20
AU2010232347A1 (en) 2011-09-29
LT2415470T (lt) 2016-10-10
IL215059A0 (en) 2011-11-30
CN102369008B (zh) 2014-10-29
BRPI1014527B8 (pt) 2021-05-25
BRPI1014527B1 (pt) 2020-11-24

Similar Documents

Publication Publication Date Title
SMT201600307B (it) Composizione liposomiale
BRPI1013588A2 (pt) composição
DK2414015T3 (da) Laryngoskopsystem
DE112010004215A5 (de) Hydrostataktor
DE112010002949A5 (de) Kupplungstastpunkte
BRPI1015474A2 (pt) composição
BRPI1008827A2 (pt) deisobutenizador
BRPI1014968A2 (pt) subalargador
DE112010002728A5 (de) Turboinhalator
DE112009005323A5 (de) Hebelarmprüfmaschine
DE112010004249A5 (de) Spindelaktor
DE112009005462T8 (de) Lenkungsssteuervorrichtung
BR112012004964A2 (pt) girocóptero
BRPI1008070A2 (pt) tricianoboratos
BRPI1005318A2 (pt) composição
DE112010004865T8 (de) Lamellennassreibkupplung
DOP2011000348A (es) Construcciones casb7439
DE112010003255A5 (de) Fördergutverteiler
BRPI1010159A2 (pt) bistuti
DE602010000025D1 (de) Fahrzeugsitzgurtvorrichtung
ES1070429Y (es) Traspaleta mejorada
DK2405753T3 (da) Insektfrastødende sammensætning
BR112012006693A2 (pt) combinação
BR112012003616A2 (pt) metilpirroloprimidinacarboxamidas
DE112010002351A5 (de) Klemmorrichtung

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61K 31/357 , A61K 9/127 , A61K 47/02 , A61K 47/18 , A61K 47/24 , A61K 47/28 , A61K 47/34 , A61K 47/36

Ipc: A61K 31/357 (2006.01), A61K 9/127 (2006.01), A61P

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/03/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF